Champix and Zyntabac units sold in Spain January 2019-20
As of the first of January 2020, the Spanish National Healthcare System began to finance varenicline and bupropion drugs to help the smoking population quit this harmful habit. These drugs, marketed as Champix (varenicline) and Zyntabac (bupropion) experienced thereafter a sharp increase in popularity reflected in the units sold in January 2020 relative to the same period in 2019. As can be seen, the sales of these smoking cessation drugs in 2020 amounted to 18.7 thousand units, representing a 300 percent growth compared to the previous year.